FDA consolidates drug application responses

Share this article:
Janet Woodcock
Janet Woodcock

The FDA has announced a new procedure for responding to drug applications.

Instead of issuing “approvable” or “not approvable” letters when a drug application is denied, the FDA's Center for Drug Evaluation and Research (CDER) will issue a “complete response” at the end of the review period, according to a statement. Complete response letters will “describe specific deficiencies and, when possible, will outline recommended actions the applicant might take to get the application ready for approval,” the statement reads.

“These new regulations will help the FDA adopt a more consistent and neutral way of conveying information to a company when we cannot approve a drug application in its present form,” said Janet Woodcock, MD, director of the CDER. According to the FDA, the revision will become effective on August 11, 2008.

The FDA currently responds to drug applications that don't cut the mustard with one of two letters: an “approvable” letter, which usually indicates that a drug is likely to be approved for marketing in the future, after specific achievable criteria is met; or a “not approvable” letter, meaning substantial changes or data would need to be submitted for the drug to be reconsidered for market approval.

Complete response letters are already used for biologic license applications, and the FDA said the change should not effect the time it takes to review a new or generic drug application, according to the statement.

Share this article:

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.